AI Agent Operational Lift for Centricity Research in Columbus, Georgia

Why AI matters at this scale

Centricity Research operates as a mid-market site management organization (SMO) with 201–500 employees, a size band where operational efficiency directly dictates competitive advantage. At this scale, the company manages dozens of active clinical trials simultaneously, generating vast amounts of patient data, regulatory documents, and site-performance metrics. Manual processing of this data creates bottlenecks that delay trial timelines and inflate costs. AI adoption is not a luxury but a lever to scale operations without proportionally increasing headcount. For a company founded in 2021 and growing rapidly, embedding AI now can establish a data-driven culture that larger, slower competitors will struggle to replicate.

Concrete AI opportunities with ROI framing

1. Intelligent patient prescreening and recruitment. The highest-leverage opportunity lies in deploying natural language processing (NLP) on electronic health records (EHRs) to automate patient-to-trial matching. A single trial can require screening thousands of records against 50+ inclusion/exclusion criteria. An AI model can reduce this screening time by 70%, directly accelerating enrollment—the most common cause of trial delays. For a network of sites, even a 10% improvement in enrollment speed translates to millions in sponsor bonuses and reduced site-idle time.

2. Automated source data verification (SDV) and data entry. Clinical research coordinators spend up to 40% of their time on manual data transcription and verification. Computer vision and NLP models can extract data from source documents and pre-populate case report forms, flagging discrepancies for human review. This reduces on-site monitoring costs and query resolution cycles, improving data quality while freeing staff for patient-facing activities.

3. Generative AI for regulatory documentation. Drafting informed consent forms, IRB submissions, and clinical study reports is labor-intensive and repetitive. Fine-tuned large language models, operating within a secure, HIPAA-compliant environment, can generate first drafts from protocol documents. This can cut document preparation time by 50%, allowing regulatory teams to focus on strategic review rather than formatting and boilerplate language.

Deployment risks specific to this size band

Mid-market organizations face unique AI risks. Unlike large pharma, Centricity cannot afford a dedicated AI research team, so it must rely on configurable, vendor-provided solutions—raising vendor lock-in and integration complexity with existing systems like Veeva or Medidata. Data privacy is paramount; any AI tool touching patient data must operate in a zero-trust, de-identified environment to avoid HIPAA violations. There is also a change-management risk: clinical staff may distrust AI-generated recommendations, requiring transparent, explainable outputs and phased rollouts. Finally, model bias in patient selection could inadvertently exclude underrepresented populations, creating regulatory and ethical liabilities that must be audited continuously.